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Although not yet fully elucidated, the science behind the mechanisms of energy homeostasis has advanced signiﬁcantly in recent decades. Current
treatment paradigms, however, have not taken advantage of this evolving body of knowledge. The use of the scalpel to treat obesity is historically rooted
in society’s perception of obesity as the result of inadequate willpowerdand not a “disease.” It is an individual’s choice to eat excessively that leads to
obesity and not a disease state to which the individual has fallen victim. Hence, to lose weight, the patient’s anatomy must be surgically altered to either
restrict nutrient intake or absorption. Endoscopic treatments have been modeled after this surgical paradigm. It is time for a new paradigm and the
development of endoscopic treatments that apply our current understanding of the physiological mechanisms that control energy homeostasis. The
author reviews the relevant aspects of the new science and offers a new treatment paradigm that is both simple and smart. A duodenal insert that slows
the passage of ingesta through the proximal small bowel is described. The device triggers both early satiation and a continuing sense of fullness to assist
in the reduction of caloric intake.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Worldwide obesity rates are staggering. According to the Cen-
ters for Disease Control, obesity rates have increased so dramati-
cally that today more than two-thirds of Americans (approximately
200million adults) are overweight or obese. Upward of $240 billion
is spent each year by the United States healthcare system on obesity
and its comorbidities.1 The World Health Organization reports that
more than 1.4 billion people worldwide are overweight or obese.
Mexico has recently surpassed the United States in terms of the
percentage of the population that is obese. Sadly, more people die
today as a result of obesity-related problems than from hunger and
malnutrition.
Endoscopic treatment of obesity and metabolic disease is
attractive because it ﬁlls a therapeutic gap betweenmedical therapy
and surgery. The inherent advantages are the lesser invasive peroral
approach and lower cost. In addition, endoscopic techniques are
applicable across a continuum of obesity and metabolic disease. To
date, endoscopic treatments have attempted to mimic the method
of action used by the various surgical approaches: restriction,
bypass, or some combination thereof. However, challenges exist at
multiple levels: (1) the complexity of device technology, resulting in
difﬁcult delivery requiring long procedure times, in addition to the
specialized training and expertise required; (2) safety proﬁle; and
(3) efﬁcacy and durability. What is needed are new paradigms of
treatment that keep endoscopic treatment simple and smart,
derived from an understanding of the physiological triggers behindPaul May and Frank Stein Interventional Endoscopy Center, California Paciﬁc Medical Cente
Received 23 August 2013; Revised 10 September 2013; Accepted 11 September 2013
* Interventional Endoscopy Services, California Paciﬁc Medical Center, 2351 Clay Stree
E-mail address: BinmoeK@sutterhealth.org (K.F. Binmoeller).
2213-1795/$ – see front matter Copyright  2013, Society of Gastrointestinal Interventi
http://dx.doi.org/10.1016/j.gii.2013.09.006obesity and metabolic disease, rather than the surgical paradigm of
simply restricting or diverting food intake.
The “surgical” paradigm in endoscopic approaches
The “surgical” paradigm for the treatment of obesity consists of
approaches that restrict and/or bypass the normal passage of
alimentation in the gastrointestinal tract. Restrictive operations
consist of either a reduction in the size of the stomach (e.g., sleeve
gastrectomy) or narrowing of the stomach inlet (lap band proce-
dure). Bypass operations divert food from contact with the small
bowel (e.g., jejunoileal bypass). The gastric bypass and duodenal
switch operations combine restrictive and bypass approaches.
Endoscopic treatments are modeled after the surgical paradigm.
The gastric balloon, the ﬁrst antiobesity treatment introduced in
the 1980s, mimics a restrictive operation by occupying space in the
stomach. With the development of novel technologies that enable
endoscopic suturing and stapling, endoscopists are able to reduce
the size of the stomach, similar to a sleeve gastrectomy, or restrict
the stomach inlet, similar to a lap band.1 Endoscopic devices that
incorporate sleeves that prevent contact of nutritionwith the small
bowel mimic a surgical bypass. Sleeves available in some countries
today range from 60 cm to 90 cm in length, anchor with barbs
proximally in either the bulb of the duodenum or the cardia and
extend to the distal jejunum.
These and other endoscopic platforms use complex tools and
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specialized training. Procedure times can be longdoften in the
multiples of standard therapeutic procedures such as polypectomy
dand unpredictable, further complicating patient scheduling.
Postprocedural pain and intolerance may necessitate considerable
inpatient and outpatient management.
The surgical paradigm: ﬂawed and antiquated?
The treatment of obesity with the surgical paradigm is certainly
not intuitive. Unlike a tumor or inﬂamed organ, the “disease”
cannot be excised with the scalpel. What then is the genesis of the
surgical paradigm? The use of the scalpel to treat obesity is his-
torically rooted in society’s perception of obesity as a problem of
willpowerdand not a disease. It is an individual’s choice to eat
excessively that leads to obesity and not a disease state to which
the individual has fallen victim. Hence, to lose weight, the indi-
vidual must be forced to either eat less or absorb less. Not sur-
prisingly, a restrictive operation that reduces the size of the
stomach to the size of an egg can very effectively force a person to
eat less. Or, bypassing the small intestine (where food absorption
occurs) can very effectively force a person to absorb less.
Whether done surgically or endoscopically, the surgical para-
digm is rooted in negative conditioning. Eating too fast or toomuch
triggers symptoms of discomfort, nausea and vomiting, and altered
bowel habits (diarrhea, frequency, ﬂatulence) that discourage
further eating. Obviously, such adverse symptoms take a substan-
tial toll on quality of life, and have a negative impact on social in-
teractions that revolve around eating. Consequently, negative
conditioning strategies often fail over time because of behavior
changes that minimize the negative symptoms (e.g., consumption
of high-calorie slurries). In addition, there is compensatory adap-
tation such as stretching of the stomach after gastric reduction.
Satiation, satiety, and the “gut–brain” axis
The body achieves energy homeostasis through an accurate
sensing of energy intake and energy utilization. Two opposing
urgesdthe need to eat to avoid starvation and the need to stop
eating to prevent excess weight accumulationdare primarily
regulated by the nervous system and gut peptides: the “gut–brain
axis.” First described several decades ago, this axis comprises
complex pathways enabling gut peptides to acts as both endocrine
hormones and paracrine neurotransmitters to affect neurons in the
hypothalamic and brain stem centers that regulate appetite.
“Satiation” refers to processes that promote meal termination,
thereby limiting meal size. “Satiety” refers to postprandial pro-
cesses that affect the interval to the next meal and thereby meal
frequency.2 This differentiation is important when considering
speciﬁc physiologic neural and humoral signals and pathways that
regulate eating behavior. In common parlance, and even in the
literature, the term “satiety” is often erroneously used to describe
processes that affect meal termination.
The role of the stomach
Filling of the stomach with ingested food is widely perceived to
be the key trigger of satiation, mediated by stretch receptors in the
stomach wall. Animal studies have shown that rats with externally
applied cuffs to the pylorus that block the passage of food into the
duodenum will terminate eating when given a large meal.3 This
was attributed to gastric distention, because rats with pyloric cuffs
fed smaller, more physiological meals did not terminate eating
earlier compared to rats without pyloric cuffs. Conversely, when
food is drained from the stomach through an open gastric ﬁstula,the animal will not terminate eating as long as the food is allowed
to drain externally.4 Although these observations support gastric
ﬁlling as a mediator of satiation, they do not implicate the stomach
as the primary source of satiation signals. In the animals with
externally applied pyloric cuffs,3 the amount of food required to
trigger meal termination far exceeded that eaten in a typical meal.
Interestingly, when rats were allowed to eat for 20 minutes with
the pylorus open prior to cuff closure (preloading), they ate less
after the closure compared to animals that had no preloading. In
the animals with open gastric ﬁstulas, all ingested food drained
prior towhen it could enter the small intestine, eliminating any role
the intestine might play in mediating satiation and raising the
possibility that this may have contributed to continuous eating. The
role of the stomach becomes more obscure when we consider that
up to 40% of a meal has emptied into the intestine prior to meal
termination.5 Thus, distention of the stomach and entry of food into
the intestine are virtually simultaneous. The chemical constitution
or energy content of food has not been found to trigger satiation in
the stomach. In cuffed animals, isotonic saline produced volume
related reductions of intake equivalent to the same volumes of an
energy dense diet. Nutrient concentration, osmotic concentration,
and pH also had no differential effect on food intake.6
The role of the duodenum
The above-mentioned animal cuff studies provided the ﬁrst
evidence that the duodenum plays a role in meal cessation.
Comparing the amounts of food eaten by rats with open and closed
cuffs, rats with an open cuff (pylorus) terminated eating more
quickly and ate less than rats with a closed cuff.7 In human vol-
unteers, infusion of lipid solutions into the duodenum reduced the
sensation of hunger prior to a meal and slowed the rate of inges-
tion.8 This effect did not occur when the same lipid solutions were
infused into the bloodstream. The suppression of hunger by the
duodenal lipid may explain why eating a bar of chocolate prior to a
meal “spoils the appetite.” This is typically after a delay of about 15–
30 min, which corresponds to entry of the chocolate into the du-
odenum with gastric emptying. Other physiological experiments
have shown that enrichment of a breakfast with fat without any
change in the amount of food consumed suppressed feelings of
hunger for lunch 4 hours later and reduced food consumption at
that meal.9
In animal and human models, both real and sham feeding are
reduced by intestinal infusions of all three macronutrient groups:
carbohydrates, fats, and amino acids. In a clinical study to deter-
mine the relative sensitivity of the duodenum to different macro-
nutrients, lipids, glucose, and a control solution (saline) were
alternatively infused into the duodenum prior to meals to 20 male
volunteers.10 When infused in equienergetic aliquots, lipids sup-
pressed energy intake by 22% compared with the control infusion
and by 15% compared with the glucose infusion. Thus, the duo-
denum responded not only to the presence and volume of nutri-
ents, but also deferentially to the caloric content of the nutrient.
The return of hunger (satiety) has been found to be directly related
to a decline in the exposure of the upper small intestine to nutrient
stimuli.
Cholecystokinin
Satiatiation signals are triggered as soon as chyme enters the
duodenum. These signals are mediated by peptides that are
released from enteroendocrine cells in the intestinal wall. The
peptides diffuse through the wall of the gut to activate nearby
vagal- and spinal afferent ﬁbers from neurons within the ganglia.
Peptides also enter the bloodstream to act distantly as hormones.
Gastrointestinal Intervention 2013 2(2), 82–8684The peptides therefore act as both neurotransmitters and
hormones.
There is a wealth of evidence supporting cholecystokinin (CCK)
as the key peptide mediating both satiation and satiety. CCK was
described ﬁrst about four decades ago, although its existence was
suggested as early as 1906.11 CCK is produced and stored in the
epithelium of the duodenum (I cells) and released in response to
the passage of nutrient byproducts such as lipids and peptides. CCK
acts as a neurotransmitter activating vagal afferents, and these
vagal afferents in turn trigger or communicate with various centers
in the hypothalamus and the hindbrain and the brain stem. It also
acts as a hormone and acts directly on the brain. The result is that
meal size is reduced (satiation), and the desire to eat between
meals is suppressed (satiety).
CCK also acts locally on neurons in the enteric nervous system to
regulate motility, digestive enzyme and ﬂuid secretion, and sec-
ondary peptide secretion. CCK has a stimulatory or amplifying role
on the gall bladder (contraction), the liver (bile acids secretion), and
the exocrine pancreas (digestive enzyme secretion). CCK also acts
as an incretin to stimulate the beta cells of the pancreas to release
insulin. CCK inhibits stomach motility (creating gastric paralysis)
while simultaneously stimulating the contraction of the pylorus,
thereby preventing food from exiting the stomach into the duo-
denum. This is consistent with a physiological shift from an
ingestive to a digestive phase (Fig. 1).
CCK is the only conﬁrmed physiological satiety peptide. There is a
temporal link between nutrient-stimulated CCK secretion and the
inhibitionof food intake. Thishas beendemonstrated inmanystudies.
The infusion of CCK at physiological doses reduces food intake and
stimulates the feelingof fullness inhumans.12 In the sham-fed ratwith
an open gastric ﬁstula, intravenous CCK reduced intake compared to
persistent eating in rats that did not receive CCK.11 CCK may work in
synergy with other anorexic neuropeptides, such as GLP-1 and PYY
produced in the distal ileum, and leptin produced by adipose tissue
have been found to amplify the action of CCK.13
Blocking CCK receptors antagonizes the satiating effects of CCK.
In humans, administration of MK-329, a speciﬁc peripheral-type
CCK receptor antagonist, leads to increased meal size.14 OtsukaFig. 1. Physiologic role of CCK on the enteric and central nervous systems (ENS, CNS).Long–Evans Tokushima Fatty rats that lack CCK1R become obese
owing to an increase in meal size and overall hyperphagia,
compared to control rats.15
The ideal endoscopic treatment
The ideal endoscopic treatment should follow a physiological
mechanism of action and preserve normal anatomy. It should allow
the patient to eat normally and maintain normal absorption, with
the intention of only reducing caloric intake. It should have no
adverse side effects and should not burn bridges to other possible
therapies. If the treatment is not tolerated or ineffective, the device
should be removable. Removability may also be desired if the
treatment has achieved its therapeutic goal, in which case repeat-
ability should be an option.
The hallmark of a successful endoscopic device is simplicity of
design. Historical examples are the polypectomy snare, sphincter-
otome, and Dormia basket. The device should be easy to deploy and
the procedure should be quick to perform, without requiring any
special skills or training.
Duodenal ﬂow restrictor
The authorhasdevelopedand is testing aduodenalﬂowrestrictor
(SatiSphere Duodenal Insert, EndoSphere Inc., Columbus, OH, USA)
designed to amplify physiologic satiety signals generated in the du-
odenum (Fig. 2A). The device has multiple mesh spheres that act as
“speed bumps” to reduce the ﬂow of chyme in the duodenum
(Fig. 2B). This prolongs the contact time of by-products of nutrition
with the lining of the duodenum,which stimulates receptors such as
CCK-A on the I cells to release anorectic neuropeptides. The disten-
tion of the duodenum by chyme may also stimulate the ﬁring of
baroreceptors. The soft spheres distributed along the length of the
backbone exert gentle contact with the duodenal wall, stimulating
the mechanoreceptors. The signaling from multiple receptors am-
pliﬁes the satiation effect, “tricking” the brain into believing that
adequate amounts of food have been consumed, leading to meal
termination. Maintenance of this stimulatory effect may occur by aCCK, cholecystokinin; CNS, central nervous system; EMS, enteric nervous systems.
Fig. 2. SatiSphere device. Mesh spheres are distributed along the length of a (A) nitinol backbone, acting as “speed bumps” that (B) delay the passage of chyme. (C) The open mesh
retains the ingestate within them for a longer period. (D) Endoscopic removal through an overtube.
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products in the open mesh spheres and continuous mechanical
contact of the device with the duodenal wall (Fig. 2C). Additionally,
GLP-1 and fatty acid metabolites such as long-chain fatty acid acyl-
CoA may act as incretins, having a beneﬁcial effect on diabetes.
A ﬁrst-generation SatiSphere device was evaluated in a 2:1
randomized clinical study in 31 patients with a mean body mass
index of 41.3 kg/m2.16 Twenty-one patients were treated with the
device and compared with 10 controls. Weight loss after 3 months
was 6.7 kg in patients completing therapy and 2.2 kg in the control
group. Excess weight loss was signiﬁcantly increased by the Sati-
Sphere device (18.4% in completers and 4.4% in controls (P ¼ 0.02),
resspectively. Dietary restrictions were not imposed. Patients
commented that they were no longer able to eat large meals and
had lost the desire to eat between meals. Measuring glucose, in-
sulin, and glucagon-like peptide 1 (GLP-1) following a mixed-meal
test with the device in place and after removal (n¼7), the Sati-
Sphere device delayed glucose absorption and insulin secretion and
altered kinetics in GLP-1 levels. The SatiSphere insert was found to
be consistently deliverable in less than 15 minutes and removable
in less than 10 minutes.
A high rate of device migration (nearly 50%) in patients treated
with the ﬁrst-generation SatiSphere device has led to the devel-
opment of a second-generation device that adds a proximal anchor
in the stomach to prevent distal migration. There are no sutures,
clips, or barbs that might damage the tissues. Unpublished pilot
data using the second-generation device have shown this conﬁg-
uration to withstand the force of peristalsis that moves contents
aborally through the gut.
The SatiSphere device is deployed by ﬁrst advancing the endo-
scope to the transverse duodenum. The insert is then pushed
through the working channel (the proximal anchor and spheres
collapse to allow for passage through the scope). As the insert be-
gins to exit from the scope, the scope is withdrawn at the same rate,
in a one-to-one fashion, no different than placement of a stent. The
spheres and proximal anchor expand as they exit the scope.The device can be removed endoscopically through a proprietary
overtube (Fig. 2D).
Conclusion
The historical treatment of obesity is rooted in the surgical
paradigms of forcing the patient to eat less or absorb less. This was
founded on the perception of obesity as a problem of willpower,
rather than a disease. Today, obesity is widely recognized as a
metabolic disease. Our understanding of the mechanisms of the
physiological control of hunger and satiety opens the door to new
therapies. The duodenum, with its production of anorexic and
incretin peptides, has come to occupy a central place in the complex
neuroendocrine interactions that underlie the regulation of energy
balance. What we need are simple and smart devices that restore
physiologic pathways. Themechanical model is giving way to a new
physiological model that treats the severe disturbances in energy
and nutrient balance.
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